Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases

BACKGROUND: Patients with HER2+ breast cancer (BC) frequently develop leptomeningeal metastases (LM). While HER2-targeted therapies have demonstrated efficacy in the neoadjuvant, adjuvant, and metastatic settings, including for parenchymal brain metastases, their efficacy for patients with LM has no...

Descripción completa

Detalles Bibliográficos
Autores principales: Lazaratos, Anna-Maria, Maritan, Sarah M., Quaiattini, Andrea, Darlix, Amelie, Ratosa, Ivica, Ferraro, Emanuela, Griguolo, Gaia, Guarneri, Valentina, Pellerino, Alessia, Hofer, Silvia, Jacot, William, Stemmler, Hans-Joachim, van den Broek, Marcel P.H., Dobnikar, Nika, Panet, Francois, Lahijanian, Zubin, Morikawa, Aki, Seidman, Andrew D., Soffietti, Riccardo, Panasci, Lawrence, Petrecca, Kevin, Rose, April A.N., Bouganim, Nathaniel, Dankner, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300571/
https://www.ncbi.nlm.nih.gov/pubmed/37156650
http://dx.doi.org/10.1016/j.breast.2023.04.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300571/
https://www.ncbi.nlm.nih.gov/pubmed/37156650
http://dx.doi.org/10.1016/j.breast.2023.04.008

Ejemplares similares